// App-Quantinova.ai

375.0 : Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study.

Researchers

Presenter

  • Helen Guo

Principal Investigators

  • Ruby Redmond-Misner

  • Wanrudee Isaranuwatchai

  • Lucy Qiao

  • Craig Earle

  • Scott R. Berry

  • James Joseph Biagi

  • Stephen Welch

  • Brandon Matthew Meyers

  • Nicole Mittmann

  • Natalie G. Coburn

  • Aliya Pardhan

  • Jessica Arias

  • Deborah Schwartz

  • Scott Gavura

  • Leta Marie Forbes

  • Robin McLeod

  • Erin Diane Kennedy

  • Kelvin K. Chan

Medical Centers

  • Cancer Care Ontario, Toronto, ON, Canada

  • Pharmacoeconomics Research Unit, Cancer Care Ontario, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Queen's University/Cancer Centre of SE Ontario, Kingston, ON, Canada

  • London Regional Cancer Centre, London, ON, Canada

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • HOPE Research Centre, Sunnybrook Hospital, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre and Odette Cancer Centre, Toronto, ON, Canada

  • Hamilton Regional Cancer Center, Hamilton, ON, Canada

  • Mount Sinai Hospital, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Adenomatous Polyposis Coli

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved